⏳ Fetching live dividend data...
Home › Calculator › GNHAY Dividend Calculator 2026
Vifor Pharma AG · OTC
Price: $38.39 · Annual div: $0.41/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in GNHAY → $7925124.23M in 10 years · $659,960,702,502.54/month
Vifor Pharma AG is a pharmaceutical enterprise dedicated to the research, production, and global commercialization of medicines, with operations spanning Switzerland, the rest of Europe, the United States, and other international markets. Its current product offerings include Ferinject/Injectafer, an injectable ferric carboxymaltose solution for treating iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex specifically formulated for infants, children, adolescents, and pregnant individuals experiencing iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) targeting symptomatic anemia associated with chronic kidney disease (CKD). The company's portfolio also features Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose formulation used to address iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder developed for managing hyperphosphatemia in adult CKD patients undergoing dialysis. Additionally, Vifor Pharma AG provides Rayaldee, an oral, extended-release calcifediol preparation for secondary hyperparathyroidism in CKD patients, and Veltassa, prescribed for hyperkalemia in both CKD and chronic heart failure patients. Looking to the future, Vifor Pharma AG is actively developing several innovative therapies. These include Vadadustat, an experimental oral hypoxia-inducible factor prolyl hydroxylase inhibitor being investigated for conditions related to oxygen availability; Avacopan, an orally-administered, highly selective C5aR1 inhibitor for orphan and rare renal disorders; ANG-3777, aimed at transplant-associated acute kidney injury; Difelikefalin, addressing chronic kidney disease-associated pruritus; and VIT-2763, designed for beta-thalassemia. Founded in 1872 and headquartered in Sankt Gallen, Switzerland, Vifor Pharma AG maintains strategic alliances with Fresenius Kabi and Zeria Pharmaceutical. As of March 22, 2022, the company functions as a subsidiary of CSL Behring AG.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GNHAY position with:
Real after-tax yield depends on where you live and how you hold GNHAY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.07% | -1.73% | $107 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.91% | -1.89% | $91 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.86% | -1.94% | $86 / yr |
| 🇬🇧 UK ISA | 0% | 1.07% | -1.73% | $107 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.98% | -1.82% | $98 / yr |
| 🇨🇦 TFSA | 0% | 1.07% | -1.73% | $107 / yr |
| 🇨🇦 CA Taxable | 25% | 0.80% | -2.00% | $80 / yr |
| 🇦🇺 Super (pension) | 15% | 0.91% | -1.89% | $91 / yr |
| 🇦🇺 AU Taxable | 30% | 0.75% | -2.05% | $75 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.79% | -2.01% | $79 / yr |
| 🇫🇷 FR Taxable | 30% | 0.75% | -2.05% | $75 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.41/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GNHAY pays quarterly — 4 times per year. Next ex-div: TBD.
How GNHAY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GNHAY sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GNHAY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Vifor Pharma AG (GNHAY) is currently trading at $38.39, trading near its 52-week high. The current dividend yield is 1.07% based on an annual payout of $0.41 per share.
Vifor Pharma AG (GNHAY) is a healthcare stock currently trading at $38.38 with a dividend yield of 1.07%. The company pays an annual dividend of $0.41 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, GNHAY has grown its dividend at a compound annual rate of 62.6%.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever